carmustine has been researched along with Neoplasms in 128 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 9.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| " The feasibility of administering various sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TEM) in patients with advanced solid neoplasms was evaluated in this Phase I and pharmacological study to assess this premise in the clinical setting." | 9.11 | A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ( Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR, 2004) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 5.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| " The feasibility of administering various sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TEM) in patients with advanced solid neoplasms was evaluated in this Phase I and pharmacological study to assess this premise in the clinical setting." | 5.11 | A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ( Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR, 2004) |
| " The terminal phase half-life was similar after intravenous (58." | 2.71 | SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ( Alaoui-Jamali, M; Bangash, N; Batist, G; Melnychuk, D; Miller, WH; Panarello, L; Panasci, L; Patenaude, F; Sandor, V; Sausville, E; Stinson, SF, 2003) |
| "Pharmacokinetic values are derived from cancer patients participating in a phase I trial (10 or 20 mg/m2 of O6-benzylguanine in a single bolus dose or 10 to 120 mg/m2 as a 60-min constant infusion)." | 2.71 | Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. ( Boczko, EM; Gerson, SL; Hoppel, CL; Ingalls, ST; Li, X; Majka, S; Spiro, TP; Tserng, KY; Willson, JK, 2003) |
| "Breast cancer patients treated with the VIPE regimen (including pretreated women) had a significantly higher CFU-GM rate than patients treated with EC (P=0." | 2.69 | Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells. ( Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W, 1998) |
| "Paclitaxel was given alone (one patient), with cyclophosphamide and cisplatin (two patients), and with cyclophosphamide and cisplatin plus 1,3-bis(2-chloroethyl)-1-nitrosourea (three patients)." | 2.69 | Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. ( Barón, A; Bearman, SI; Cagnoni, PJ; DeBoom, T; Jones, RB; Matthes, S; Nieto, Y; Shpall, EJ, 1999) |
| " We reviewed the AUC of CPA in 470 patients who underwent pharmacokinetic monitoring of the drug." | 2.69 | Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Murphy, J; Nieto, Y; Shpall, EJ; Xu, X, 1999) |
| "Early phase evaluation of anticancer drugs has traditionally used toxicity (usually hematological) rather than efficacy end points to establish appropriate dosing schedules." | 2.69 | O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. ( Gerson, SL; Haaga, J; Hoppel, CL; Ingalls, ST; Liu, L; Majka, S; Pluda, JM; Spiro, TP; Willson, JK, 1999) |
| "Thymidine (dThd) has been shown to increase the activity of BCNU in mice, possibly due to its ability to inhibit poly(ADP-ribose)polymerase (PADPRP), an enzyme thought to be active in DNA repair." | 2.68 | A phase I pilot study of BCNU plus thymidine in patients with refractory cancer. ( Cooper, DL; Durivage, HJ; Sandler, AB; Schultz, MZ, 1996) |
| "We found that those tumors with high MGMT activity and abundance of MGMT protein were resistant to alkylating agents killing effect, while those with low MGMT activity and little MGMT protein were sensitive to alkylating anti-tumor drugs." | 2.42 | [Study on MGMT assay and tumor individual predictable chemotherapy]. ( Zhang, YP, 2004) |
| " Since no epidemiological data in man are available, extrapolation of animal data to man are important as well as dose-response studies in risk evaluations." | 2.37 | Carcinogenic N-nitroso compounds and their environmental significance. ( Preussmann, R, 1984) |
| "In small cell lung cancer initial high dose therapy followed by non-cross-resistant regimens may prove effective." | 2.37 | High dose chemotherapy in solid tumours in adults. ( Peters, W; Souhami, R, 1986) |
| "This paper provides an overview of cancer chemotherapy with special reference to the pharmacokinetics of the nitrosoureas." | 2.36 | [Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas]. ( Wakui, A, 1982) |
| "For certain cancer types, such as melanoma, gene body methylation appears to be a better predictor of MGMT transcription (compared to promoter methylation)." | 1.62 | MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types. ( Bacolod, MD; Barany, F, 2021) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| "We report a case series of childhood cancer survivors who developed an isolated thrombocytopenia in the presence of a normocellular bone marrow." | 1.33 | Immune thrombocytopenia following successful treatment of cancer in children. ( Barnes, C; Blanchette, V; Canning, P; Greenberg, M; Price, V, 2006) |
| "Histologic analysis of treated tumors confirmed spatial changes in cellularity as observed by fDM." | 1.33 | The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. ( Chenevert, TL; Hall, DE; Hoff, BA; Johnson, TD; McKeever, PE; Meyer, CR; Moffat, BA; Rehemtulla, A; Ross, BD, 2006) |
| "In the setting of target-based anticancer drug development, it is critical to establish that the observed preclinical activity can be attributed to modulation of the intended target in early phase trials in human subjects." | 1.31 | Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. ( Berger, NA; Berger, SJ; Dowlati, A; Gerson, SL; Haaga, J; Liu, L; Remick, SC; Spiro, TP; Willson, JK, 2001) |
| "Forty patients with refractory solid tumors or non-Hodgkin's lymphoma were treated with high-dose cyclophosphamide, thiotepa, and carmustine (BCNU), followed by autologous stem cell rescue, in a phase I dose escalation study." | 1.28 | High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. ( Bitran, JD; Garner, M; Kaminer, LS; Moormeier, JA; Williams, SF, 1990) |
| "Thirty-five patients with solid tumors received 44 courses of bis-chlorethylnitrosourea (BCNU) at doses ranging between 600 and 1,400 mg/m2 with cryopreserved or fresh autologous bone-marrow support." | 1.27 | Autologous bone-marrow transplantation: host effects of high-dose BCNU. ( Canellos, GP; Hochberg, FH; Parker, LM; Takvorian, T, 1983) |
| "Metronidazole, 1." | 1.27 | Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983) |
| "Of 16 evaluable patients with breast cancer, 15 responded (six complete responses)." | 1.27 | High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. ( Andersen, J; Antman, K; Eder, JP; Elias, A; Finberg, R; Henner, WD; Peters, WP; Schryber, S; Shea, T; Wilmore, D, 1987) |
| " Plating efficiency assays were used to generate BCNU dose-response survival curves for DFMO-treated and control cells." | 1.27 | Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion. ( Komar, KA; Seidenfeld, J, 1985) |
| " The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration." | 1.27 | Pharmacokinetics of high-dose melphalan in children and adults. ( Gouyette, A; Hartmann, O; Pico, JL, 1986) |
| " Nevertheless, in the absence of a significant number of life-threatening toxicities, it appears that near maximal doses of BCNU and concomitant IFN-rA can be administered with safety in an outpatient setting." | 1.27 | Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. ( Creagan, ET; Kovach, JS; Long, HJ; Richardson, RL, 1986) |
| "In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug." | 1.26 | Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study. ( Burk, MW; Campbell, MA; Giuliano, AE; Kaiser, LR; Kern, DH; Mann, BD; Morton, DL, 1982) |
| "Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B." | 1.26 | Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia. ( Klahr, C; Presant, CA; Santala, R, 1977) |
| "Ten patients developed pulmonary fibrosis after bischloroethylnitrosourea (BCNU) therapy for malignancy." | 1.26 | Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). ( Bartolucci, AA; Durant, JR; Langford, KH; Murad, TM; Norgard, MJ, 1979) |
| "Of 11 patients with measurable metastases from bronchogenic carcinoma, five had partial antitumor responses lasting 1." | 1.26 | Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results. ( Gatewood, D; Klahr, C; Olander, J; Presant, CA, 1976) |
| "Osseous, visceral, and cutaneous metastases responded equally well." | 1.26 | Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors. ( Klahr, C; Kolhouse, JF; Presant, CA, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 81 (63.28) | 18.7374 |
| 1990's | 26 (20.31) | 18.2507 |
| 2000's | 17 (13.28) | 29.6817 |
| 2010's | 2 (1.56) | 24.3611 |
| 2020's | 2 (1.56) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Bacolod, MD | 1 |
| Barany, F | 1 |
| Hahn, L | 1 |
| Lim, H | 1 |
| Dusyk, T | 1 |
| Sabry, W | 1 |
| Elemary, M | 1 |
| Stakiw, J | 1 |
| Danyluk, P | 1 |
| Bosch, M | 1 |
| WOOD, CA | 1 |
| CHARTERIS, AA | 1 |
| Xiao, Y | 1 |
| Liu, J | 2 |
| Liu, YC | 1 |
| Huang, XE | 1 |
| Guo, JX | 1 |
| Wei, W | 1 |
| Grimberg, H | 1 |
| Levin, G | 1 |
| Shirvan, A | 1 |
| Cohen, A | 1 |
| Yogev-Falach, M | 1 |
| Reshef, A | 1 |
| Ziv, I | 1 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Panasci, L | 1 |
| Stinson, SF | 1 |
| Melnychuk, D | 1 |
| Sandor, V | 1 |
| Miller, WH | 1 |
| Batist, G | 1 |
| Patenaude, F | 1 |
| Bangash, N | 1 |
| Panarello, L | 1 |
| Alaoui-Jamali, M | 1 |
| Sausville, E | 1 |
| Tserng, KY | 1 |
| Ingalls, ST | 2 |
| Boczko, EM | 1 |
| Spiro, TP | 3 |
| Li, X | 1 |
| Majka, S | 2 |
| Gerson, SL | 6 |
| Willson, JK | 4 |
| Hoppel, CL | 2 |
| SWYNGEDAUW, J | 1 |
| GIAUX, G | 1 |
| TOISON, G | 1 |
| RAMIOUL, H | 1 |
| SMITH, IH | 1 |
| KAHR, E | 1 |
| HOWARTH, J | 1 |
| WILSON, CW | 1 |
| HALL, EJ | 1 |
| DALRYMPLE, GV | 1 |
| PEREZ-TAMAYO, R | 1 |
| Pollok, KE | 1 |
| Hartwell, JR | 1 |
| Braber, A | 1 |
| Cooper, RJ | 1 |
| Jansen, M | 1 |
| Ragg, S | 1 |
| Bailey, BJ | 1 |
| Erickson, LC | 2 |
| Kreklau, EL | 1 |
| Williams, DA | 1 |
| GARRISON, H | 1 |
| ANDERSON, J | 1 |
| LAUGHLIN, JS | 1 |
| HARVEY, RA | 1 |
| Hammond, LA | 1 |
| Eckardt, JR | 1 |
| Kuhn, JG | 1 |
| Johnson, T | 1 |
| Smith, L | 1 |
| Drengler, RL | 1 |
| Campbell, E | 1 |
| Weiss, GR | 1 |
| Von Hoff, DD | 1 |
| Rowinsky, EK | 1 |
| Zhang, YP | 1 |
| Price, V | 1 |
| Barnes, C | 1 |
| Canning, P | 1 |
| Blanchette, V | 1 |
| Greenberg, M | 1 |
| Magagnoli, M | 1 |
| Masci, G | 1 |
| Castagna, L | 1 |
| Pedicini, V | 1 |
| Poretti, D | 1 |
| Morenghi, E | 1 |
| Brambilla, G | 1 |
| Santoro, A | 1 |
| Moffat, BA | 1 |
| Chenevert, TL | 1 |
| Meyer, CR | 1 |
| McKeever, PE | 1 |
| Hall, DE | 1 |
| Hoff, BA | 1 |
| Johnson, TD | 1 |
| Rehemtulla, A | 1 |
| Ross, BD | 1 |
| Kuo, CC | 1 |
| Liu, JF | 1 |
| Shiah, HS | 1 |
| Ma, LC | 1 |
| Chang, JY | 1 |
| Mann, BD | 1 |
| Kern, DH | 1 |
| Giuliano, AE | 1 |
| Burk, MW | 1 |
| Campbell, MA | 1 |
| Kaiser, LR | 1 |
| Morton, DL | 1 |
| Schlag, P | 1 |
| Wolfrum, J | 1 |
| Vergani, G | 1 |
| Schreml, W | 1 |
| Herfarth, C | 1 |
| Rubin, P | 1 |
| Wakui, A | 1 |
| Adams, GE | 1 |
| Phillips, GL | 2 |
| Fay, JW | 2 |
| Herzig, GP | 2 |
| Herzig, RH | 1 |
| Weiner, RS | 1 |
| Wolff, SN | 2 |
| Lazarus, HM | 1 |
| Karanes, C | 1 |
| Ross, WE | 1 |
| Kramer, BS | 1 |
| Takvorian, T | 2 |
| Parker, LM | 1 |
| Hochberg, FH | 2 |
| Canellos, GP | 1 |
| Preussmann, R | 1 |
| Knight, WA | 1 |
| Arrick, BA | 1 |
| Nathan, CF | 1 |
| Fingert, HJ | 1 |
| Sculier, JP | 1 |
| Klastersky, J | 1 |
| Cornbleet, MA | 1 |
| Leonard, RC | 1 |
| Smyth, JF | 1 |
| Stewart, DJ | 1 |
| Maroun, JA | 1 |
| Young, V | 1 |
| Crook, AF | 1 |
| Hopkins, HS | 1 |
| Yan, RC | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Bélanger, R | 1 |
| Heringer, R | 1 |
| Bull, JM | 1 |
| Macdonald, JS | 1 |
| Hoth, D | 1 |
| Schein, PS | 2 |
| Kaye, SB | 1 |
| Weiss, RB | 1 |
| Issell, BF | 1 |
| Robak, T | 1 |
| Spitzer, G | 2 |
| Dicke, KA | 2 |
| Litam, J | 1 |
| Verma, DS | 2 |
| Zander, A | 2 |
| Lanzotti, V | 1 |
| Valdivieso, M | 1 |
| McCredie, KB | 2 |
| Samuels, ML | 1 |
| Owen, H | 1 |
| Klove, C | 1 |
| Cotanch, PH | 1 |
| Levin, VA | 1 |
| Weinkam, RJ | 1 |
| Gomez, GA | 1 |
| Aggarwal, KK | 1 |
| Han, T | 1 |
| Liter, ME | 1 |
| Herman, TS | 1 |
| Zukoski, CF | 1 |
| Anderson, RM | 1 |
| Hutter, JJ | 1 |
| Blitt, CD | 1 |
| Malone, JM | 1 |
| Larson, DF | 1 |
| Dean, JC | 1 |
| Roth, HB | 1 |
| Dercksen, MW | 1 |
| Gerritsen, WR | 1 |
| Rodenhuis, S | 1 |
| Dirkson, MK | 1 |
| Slaper-Cortenbach, IC | 1 |
| Schaasberg, WP | 1 |
| Pinedo, HM | 1 |
| von dem Borne, AE | 1 |
| van der Schoot, CE | 1 |
| Gallardo, D | 1 |
| Alonso, E | 1 |
| Riu, C | 1 |
| Ponce, C | 1 |
| Salar, A | 1 |
| Ferrà, C | 1 |
| Berlanga, JJ | 1 |
| Grañena, A | 1 |
| Domenech, J | 1 |
| Linassier, C | 1 |
| Gihana, E | 1 |
| Dayan, A | 1 |
| Truglio, D | 1 |
| Bout, M | 1 |
| Petitdidier, C | 1 |
| Delain, M | 1 |
| Petit, A | 1 |
| Brémond, JL | 1 |
| Mitchell, RB | 1 |
| Dolan, ME | 3 |
| Janisch, L | 1 |
| Vogelzang, NJ | 2 |
| Ratain, MJ | 2 |
| Schilsky, RL | 2 |
| Lind, MJ | 1 |
| Ardiet, C | 1 |
| Stewart, FM | 2 |
| Temeles, D | 1 |
| Lowry, P | 1 |
| Thraves, T | 1 |
| Grosh, WW | 1 |
| Quesenberry, PJ | 1 |
| Schultz, MZ | 1 |
| Sandler, AB | 1 |
| Durivage, HJ | 1 |
| Cooper, DL | 1 |
| Mahendra, P | 1 |
| Johnson, D | 1 |
| Scott, MA | 1 |
| Jestice, HK | 1 |
| Hood, IM | 1 |
| Ager, S | 1 |
| Bass, G | 1 |
| Barker, P | 1 |
| Boraks, PA | 1 |
| Bloxham, DM | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 1 |
| Wedge, SR | 1 |
| Porteous, JK | 1 |
| Newlands, ES | 1 |
| Knudsen, LM | 1 |
| Gaarsdal, E | 1 |
| Jensen, L | 1 |
| Nielsen, KJ | 1 |
| Nikolaisen, K | 1 |
| Johnsen, HE | 1 |
| Aabo, K | 1 |
| Watts, MJ | 1 |
| Sullivan, AM | 1 |
| Leverett, D | 1 |
| Peniket, AJ | 1 |
| Perry, AR | 1 |
| Williams, CD | 1 |
| Devereux, S | 1 |
| Goldstone, AH | 1 |
| Linch, DC | 1 |
| Vogel, W | 1 |
| Kunert, C | 1 |
| Blumenstengel, K | 1 |
| Fricke, HJ | 1 |
| Kath, R | 1 |
| Sayer, HG | 1 |
| Höffken, K | 1 |
| Pegg, AE | 1 |
| Clark, RE | 1 |
| Brammer, CG | 1 |
| Nieto, Y | 2 |
| Cagnoni, PJ | 2 |
| Bearman, SI | 2 |
| Shpall, EJ | 2 |
| Matthes, S | 2 |
| DeBoom, T | 1 |
| Barón, A | 1 |
| Jones, RB | 2 |
| Xu, X | 1 |
| Murphy, J | 1 |
| Liu, L | 2 |
| Haaga, J | 2 |
| Pluda, JM | 1 |
| Bertucci, D | 1 |
| Ewesuedo, RB | 1 |
| Mani, S | 1 |
| Wilson, LR | 1 |
| Wäsch, R | 1 |
| Reisser, S | 1 |
| Hahn, J | 1 |
| Bertz, H | 1 |
| Engelhardt, M | 1 |
| Kunzmann, R | 1 |
| Veelken, H | 1 |
| Holler, E | 1 |
| Finke, J | 1 |
| Oberley, LW | 1 |
| Dowlati, A | 1 |
| Remick, SC | 1 |
| Berger, SJ | 1 |
| Berger, NA | 1 |
| Maranhão, RC | 1 |
| Graziani, SR | 1 |
| Yamaguchi, N | 1 |
| Melo, RF | 1 |
| Latrilha, MC | 1 |
| Rodrigues, DG | 1 |
| Couto, RD | 1 |
| Schreier, S | 1 |
| Buzaid, AC | 1 |
| Chabner, BA | 1 |
| Myers, CE | 1 |
| Coleman, CN | 1 |
| Johns, DG | 1 |
| Lokich, JJ | 1 |
| Chawla, PL | 1 |
| Frei, E | 1 |
| Presant, CA | 3 |
| Klahr, C | 3 |
| Santala, R | 1 |
| Nicolin, A | 2 |
| Paterson, AH | 1 |
| English, D | 1 |
| NaPombejara, C | 1 |
| Durant, JR | 2 |
| Norgard, MJ | 1 |
| Murad, TM | 1 |
| Bartolucci, AA | 1 |
| Langford, KH | 1 |
| Green, MR | 1 |
| Creagan, ET | 2 |
| Eagan, RT | 1 |
| Rubin, J | 1 |
| Chirigos, MA | 1 |
| Schultz, RM | 1 |
| Goldin, A | 2 |
| Bonmassar, E | 1 |
| Slavik, M | 2 |
| Hill, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, WL | 1 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Fletcher, WS | 1 |
| Golomb, FM | 1 |
| Cruz, AB | 1 |
| Frischer, H | 1 |
| Ahmad, T | 1 |
| Olander, J | 1 |
| Gatewood, D | 1 |
| Kolhouse, JF | 1 |
| Salmon, SE | 1 |
| Pearson, D | 1 |
| Micetich, KC | 1 |
| Futscher, B | 1 |
| Koch, D | 1 |
| Fisher, RI | 1 |
| Panella, TJ | 1 |
| Smith, DC | 1 |
| Schold, SC | 1 |
| Rogers, MP | 1 |
| Winer, EP | 1 |
| Fine, RL | 1 |
| Crawford, J | 1 |
| Herndon, JE | 1 |
| Trump, DL | 1 |
| Alley, MC | 1 |
| Pacula-Cox, CM | 1 |
| Hursey, ML | 1 |
| Rubinstein, LR | 1 |
| Boyd, MR | 1 |
| Negrier, S | 1 |
| Ranchere, JY | 1 |
| Philip, I | 1 |
| Merrouche, Y | 1 |
| Biron, P | 1 |
| Blaise, D | 1 |
| Attal, M | 1 |
| Rebattu, P | 1 |
| Clavel, M | 1 |
| Pourreau, C | 1 |
| Köppler, H | 1 |
| Pflüger, KH | 1 |
| Havemann, K | 1 |
| Moormeier, JA | 1 |
| Williams, SF | 1 |
| Kaminer, LS | 1 |
| Garner, M | 1 |
| Bitran, JD | 1 |
| Ayash, LJ | 1 |
| Hunt, M | 1 |
| Antman, K | 2 |
| Nadler, L | 1 |
| Wheeler, C | 1 |
| Elias, A | 2 |
| Antin, JH | 1 |
| Greenough, T | 1 |
| Eder, JP | 2 |
| Kaiser, DL | 1 |
| Ishitani, KP | 1 |
| Pirsch, GW | 1 |
| Niskanen, E | 1 |
| Burnham, N | 1 |
| Betcher, DL | 1 |
| Souhami, R | 1 |
| Peters, W | 1 |
| Slease, RB | 1 |
| Benear, JB | 1 |
| Selby, GB | 1 |
| Reitz, CL | 1 |
| Hughes, WL | 1 |
| Watkins, CL | 1 |
| Epstein, RB | 1 |
| Appelbaum, FR | 1 |
| Buckner, CD | 1 |
| Shea, T | 1 |
| Peters, WP | 1 |
| Andersen, J | 1 |
| Schryber, S | 1 |
| Henner, WD | 1 |
| Finberg, R | 1 |
| Wilmore, D | 1 |
| Lombard, CM | 1 |
| Churg, A | 1 |
| Winokur, S | 1 |
| Seidenfeld, J | 1 |
| Komar, KA | 1 |
| Gouyette, A | 1 |
| Hartmann, O | 1 |
| Pico, JL | 1 |
| Kovach, JS | 1 |
| Long, HJ | 1 |
| Richardson, RL | 1 |
| Byar, DP | 1 |
| Piantadosi, S | 1 |
| Bergevin, PR | 1 |
| Tormey, DC | 1 |
| Blom, J | 2 |
| Sigel, MM | 1 |
| Lichter, W | 1 |
| Lopez, DM | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| O'Connell, MJ | 1 |
| Hubbard, S | 1 |
| Magrath, IT | 1 |
| Bergevin, P | 1 |
| Wiernik, PH | 1 |
| Ziegler, JL | 1 |
| DeVita, VT | 1 |
| Rosenoff, SH | 1 |
| Bostick, F | 1 |
| Young, RC | 1 |
| Carter, SK | 1 |
| Schabel, FM | 1 |
| Broder, LE | 1 |
| Johnston, TP | 1 |
| Reyes, ES | 1 |
| Talley, RW | 1 |
| O'Bryan, RM | 1 |
| Gastesi, RA | 1 |
| Zubrod, CG | 1 |
| Scott, MT | 1 |
| Omura, GA | 1 |
| Roberts, GA | 1 |
| Lessner, HE | 1 |
| van Eden, EB | 1 |
| Falkson, G | 1 |
| van Dyk, JJ | 1 |
| van der Merwe, AM | 1 |
| Falkson, HC | 1 |
| Kinne, DW | 1 |
| Humphrey, EW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I and Pharmacokinetics Study of SarCNU in Patients With Advanced Cancers[NCT00003703] | Phase 1 | 0 participants | Interventional | 1999-01-31 | Completed | ||
| Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study[NCT01791387] | Phase 2 | 30 participants (Anticipated) | Interventional | 2012-03-31 | Active, not recruiting | ||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
23 reviews available for carmustine and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
[Study on MGMT assay and tumor individual predictable chemotherapy].
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Resistance, Neo | 2004 |
The Franz Buschke lecture: late effects of chemotherapy and radiation therapy: a new hypothesis.
Topics: Antineoplastic Agents; Bleomycin; Bone Marrow Diseases; Brain Diseases; Cardiomyopathies; Carmustine | 1984 |
[Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas].
Topics: Carmustine; Humans; Kinetics; Lomustine; Neoplasms; Nimustine; Nitrosourea Compounds; Semustine; Sol | 1982 |
Carcinogenic N-nitroso compounds and their environmental significance.
Topics: Alkylation; Animals; Brain Neoplasms; Carcinogens; Carcinogens, Environmental; Carmustine; Dimethyln | 1984 |
Glutathione metabolism as a determinant of therapeutic efficacy: a review.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Biological Transport; Carmustine; Cycloph | 1984 |
High-dose alkylating agent therapy: a review of clinical experiences.
Topics: Alkylating Agents; Busulfan; Carcinoma, Bronchogenic; Carmustine; Dose-Response Relationship, Drug; | 1984 |
A review of systemic hyperthermia.
Topics: Antineoplastic Agents; Carmustine; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomyc | 1984 |
Intensive chemotherapy for solid tumours--current clinical applications.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Com | 1982 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance.
Topics: Alkylating Agents; Biological Transport; Carmustine; Clinical Trials as Topic; DNA Damage; DNA Repai | 1995 |
Pharmacokinetics of alkylating agents.
Topics: Alkylating Agents; Carmustine; Chlorambucil; Cyclophosphamide; Humans; Ifosfamide; Lomustine; Melpha | 1993 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmust | 1996 |
Cellular heterogeneity in malignant tumors. The importance of clonal interaction on tumor evolution, response to chemotherapy and metastatic ability evaluated in experimental systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Communication; Clone Cells; Humans; Mic | 1996 |
O6-benzylguanine and its role in chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA Repa | 1997 |
Anticancer therapy by overexpression of superoxide dismutase.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antioxidants; Carmustine; Cricetinae; Genetic Therapy; | 2001 |
Experimental chemoimmunotherapy of cancer.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Immunotherapy; Leukemia L1210; Male; N | 1978 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Guide to the use of cancer chemotherapeutic agents.
Topics: Alkylating Agents; Allopurinol; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; | 1972 |
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cell-Free System; | 1972 |
Present status of cancer chemotherapy.
Topics: Alkylating Agents; Animals; Anti-Bacterial Agents; Antimetabolites; Carmustine; DNA, Neoplasm; Evalu | 1974 |
Corynebacterium parvum as an immunotherapeutic anticancer agent.
Topics: Animals; Carmustine; Corynebacterium; Humans; Immunity; Immunity, Cellular; Immunotherapy; Lectins; | 1974 |
27 trials available for carmustine and Neoplasms
| Article | Year |
|---|---|
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin | 2014 |
SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Carmustine; Femal | 2003 |
Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine.
Topics: Aged; Antineoplastic Agents, Alkylating; Carmustine; Enzyme Inhibitors; Female; Guanine; Half-Life; | 2003 |
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Car | 2004 |
[Use of nitrosourea compounds in cancer chemotherapy].
Topics: Carmustine; Clinical Trials as Topic; Humans; Lomustine; Neoplasms; Nitrosourea Compounds; Semustine | 1982 |
Comparative pharmacokinetics of 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)-1-nitrosourea in rats and patients and extrapolation to clinical trials.
Topics: Animals; Carmustine; Clinical Trials as Topic; Drug Evaluation; Gas Chromatography-Mass Spectrometry | 1981 |
Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug | 1982 |
Sequential therapy with dacarbazine and carmustine: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Drug Administr | 1994 |
Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine | 1993 |
A phase I pilot study of BCNU plus thymidine in patients with refractory cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Female; Human | 1996 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmust | 1996 |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; | 1998 |
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1999 |
Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neopl | 1999 |
O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Biotransformation; Breast Neoplasms; Carmust | 1999 |
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dose-Res | 2000 |
Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Female; Follow-Up S | 2000 |
1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Topics: Adolescent; Adult; Aged; Bone Marrow; Carmustine; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
Clinical studies with DTIC (NSC-45388) in various malignancies.
Topics: Adult; Carmustine; Child; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Comb | 1976 |
Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Administration Schedul | 1992 |
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
Topics: Adult; Aged; Alkaline Phosphatase; Carmustine; Drug Administration Schedule; Drug Evaluation; Drug R | 1992 |
Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
Topics: Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Drug Administration Sched | 1991 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
Topics: Adenoma, Islet Cell; Blood Cells; Burkitt Lymphoma; Carcinoid Tumor; Carmustine; Clinical Trials as | 1974 |
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cell-Free System; | 1972 |
Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Topics: Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Clinical Trials as Topic; Edema; Fluoxymeste | 1973 |
81 other studies available for carmustine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Computational Biology; CpG Islands; | 2021 |
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fema | 2021 |
Radium beam therapy.
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium | 1951 |
Radium beam therapy at the Western Infirmary of Glasgow, 1938-48.
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium | 1951 |
Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
RADIO-COBALT beam therapy.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Neoplasms; Radioactivity | 1953 |
[Utilization of contiguous orthogonal beams in the treatment of semi-deep-seated tumors].
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms | 1953 |
[Contribution to the study of convergence beam radiotherapy].
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radiotherapy | 1956 |
Cobalt 60 beam therapy: some impressions after five years.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Melphalan; Neoplasms; Radioactivity | 1957 |
[Technic of moving beam therapy in cancer of esophagus].
Topics: Carmustine; Esophageal Neoplasms; Humans; Melphalan; Neoplasms; Radiotherapy | 1957 |
Moving-beam therapy with cobalt 60: its adaptability to the lesion shape to be treated.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Humans; Neoplasms; Radioactivity | 1961 |
A ROTA-WEDGE TECHNIC FOR THERAPY WITH HIGH-ENERGY RADIATION BEAMS.
Topics: Carmustine; Humans; Neoplasms; Radiotherapy, High-Energy | 1964 |
In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations.
Topics: Animals; Antigens, CD34; Antineoplastic Agents, Alkylating; Carmustine; Cell Differentiation; Cell D | 2003 |
Comparison of dose distributions in patients treated with x-ray beams of widely different energies.
Topics: Carmustine; Humans; Neoplasms; X-Rays | 1952 |
Immune thrombocytopenia following successful treatment of cancer in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Carmustine; Child, | 2006 |
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients.
Topics: Administration, Oral; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Ca | 2006 |
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2006 |
Tamoxifen accelerates proteasomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells.
Topics: Carmustine; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, N | 2007 |
Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Hepatocellular; Carmustine; Cell Division; D | 1982 |
[Growth of tumour-cell colonies from human solid tumours (author's transl)].
Topics: Carmustine; Cisplatin; Clone Cells; Doxorubicin; Drug Resistance; Fluorouracil; Humans; In Vitro Tec | 1982 |
Radiosensitizers: a conference preview.
Topics: Animals; Aziridines; Buthionine Sulfoximine; Carmustine; Combined Modality Therapy; Drug Synergism; | 1984 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Central Nervous S | 1983 |
Autologous bone-marrow transplantation: host effects of high-dose BCNU.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Hematopoiesis; | 1983 |
Autologous bone marrow transplantation for human solid tumors.
Topics: Bone Marrow Transplantation; Carmustine; Humans; Melphalan; Neoplasms; Transplantation, Autologous | 1984 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Perspectives for the use of high-dose chemotherapy in the treatment of solid malignant tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1984 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity.
Topics: Animals; Bone Marrow; Carmustine; Drug Evaluation; Drug Evaluation, Preclinical; Female; Humans; Leu | 1980 |
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug | 1980 |
Bone marrow harvesting and high-dose BCNU therapy: nursing implications.
Topics: Biopsy, Needle; Bone Marrow Transplantation; Carmustine; Humans; Neoplasms; Suction; Transplantation | 1981 |
Management of drug toxicities and infections.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Humans; Infections; Met | 1980 |
Whole-body hyperthermia and chemotherapy for treatment of patients with advanced, refractory malignancies.
Topics: Adult; Antineoplastic Agents; Burns; Carmustine; Child; Cisplatin; Evaluation Studies as Topic; Fema | 1982 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bon | 1995 |
Bone marrow transplantation through standard central venous catheters.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Catheteriza | 1995 |
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1995 |
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening A | 1996 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bloo | 1996 |
Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell | 1998 |
Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophospham | 1998 |
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Topics: Animals; Antineoplastic Agents; Biopsy; Carmustine; Cisplatin; Clinical Trials, Phase I as Topic; Cl | 2001 |
Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Survival; Drug Carriers; E | 2002 |
The clinical pharmacology of antineoplastic agents (second of two parts).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Bleomycin; Carmustine; Cel | 1975 |
Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.
Topics: Adult; Aged; Amphotericin B; Breast Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resis | 1977 |
High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
Topics: Adult; Aged; Bone Marrow Transplantation; Carcinoma; Carmustine; Female; Freezing; Humans; Male; Mel | 1979 |
The effect of BCNU combined with total body irradiation or cyclophosphamide on survival of dogs after autologous marrow grafts.
Topics: Animals; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Dogs; Drug Therapy, | 1979 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) autologous bone marrow transplantation therapy of refractory cancer: a preliminary report.
Topics: Bone Marrow Transplantation; Carmustine; Leukocyte Count; Neoplasms; Neutrophils; Platelet Count | 1979 |
Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU).
Topics: Adolescent; Adult; Aged; Carmustine; Cough; Dyspnea; Female; Humans; Hypoxia; Lymphoma; Male; Middle | 1979 |
Pulmonary toxicity in cancer chemotherapy.
Topics: Antineoplastic Agents; Carmustine; Female; Humans; Lung Diseases; Neoplasms; Pneumonia; Prednisone | 1979 |
Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
Topics: Bone Marrow; Carmustine; Dianhydrogalactitol; Drug Evaluation; Female; Humans; Male; Middle Aged; Ne | 1979 |
Animal models in cancer research which could be useful in studies of the effect of alcohol on cellular immunity.
Topics: Adrenal Cortex Hormones; Alcoholism; Animals; Carmustine; Disease Models, Animal; Humans; Immunity, | 1979 |
Rationale of chemotherapeutic adjuvant treatment.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Admi | 1978 |
Interrelationship between chemotherapy and immunotherapy in the treatment of disseminated disease.
Topics: Animals; Carmustine; Dacarbazine; Humans; Immunity; Immunotherapy; Leukemia L1210; Methotrexate; Mic | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU" [1,3-bis(chloroethyl)-1-nitrosourea].
Topics: Animals; Ascorbic Acid; Carmustine; Dose-Response Relationship, Drug; Erythrocytes; Female; Glutathi | 1977 |
Clinical studies with nitrosoureas in various solid tumors.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Female; Genital Neoplasms, F | 1976 |
Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
Topics: Amphotericin B; Blood Platelets; Bone Marrow; Carmustine; Drug Therapy, Combination; Granulocytes; H | 1976 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Cyclophosp | 1976 |
Nitrosoureas: important new drugs for the treatment of cancer.
Topics: Carmustine; Humans; Lomustine; Neoplasms; Nitrosourea Compounds | 1976 |
Proceedings: Advances in the treatment of malignant disease in children.
Topics: Carmustine; Child; Cyclophosphamide; Dactinomycin; Humans; Neoplasms; Vincristine | 1976 |
Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.
Topics: Bleomycin; Carmustine; Cell Division; Cell Line; Chlorambucil; Cisplatin; Colony-Forming Units Assay | 1991 |
High-dose chemotherapy with autologous bone marrow rescue: haematopoietic reconstitution by non-cryopreserved marrow.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1991 |
High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies.
Topics: Adult; Alkylating Agents; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Hematopoi | 1990 |
Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.
Topics: Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Female; Hepatic Veno-Occl | 1990 |
Modulation of human lymphocyte O6-alkylguanine-DNA alkyltransferase by streptozotocin in vivo.
Topics: Carmustine; Cisplatin; DNA Repair; DNA, Neoplasm; Drug Resistance; Humans; Lomustine; Lymphocytes; M | 1989 |
Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Form | 1989 |
BCNU (carmustine).
Topics: Carmustine; Humans; Neoplasms | 1989 |
High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Bone Marrow Transplanta | 1988 |
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1987 |
Pulmonary veno-occlusive disease following therapy for malignant neoplasms.
Topics: Adolescent; Adult; Biopsy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Hodgkin D | 1987 |
Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion.
Topics: Carmustine; Cell Division; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Eflorni | 1985 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer.
Topics: Adult; Aged; Carmustine; Cell Line; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Fema | 1986 |
Factorial designs for randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biometry; Carmustine; Clinical Trials as Topic; Drug | 1985 |
In vitro methods to complement in vivo approaches utilizing combinations of chemotherapy and immunotherapy.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Bleomycin; Carmustine; Cells, Cultured; Chickens | 1974 |
Alterations induced by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in deoxyribonucleic acid synthesis in normal and tumorous tissues. Implications for optimal chemotherapy.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Carmustine; DNA; DNA, Neoplasm; Dose-Response Relations | 1974 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
Development of four-drug BCNU combination chemotherapy regimens.
Topics: Carmustine; Cyclophosphamide; Evaluation Studies as Topic; Hematologic Diseases; Hodgkin Disease; Hu | 1973 |
5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
Topics: Adult; Aged; Alkylating Agents; Amides; Carmustine; Drug Combinations; Female; Fluorouracil; Humans; | 1972 |
Combined therapy with cytosine arabinoside (NSC-63878) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for advanced solid tumors.
Topics: Adult; Alkylating Agents; Blood Cell Count; Carmustine; Cytarabine; Drug Combinations; Humans; Male; | 1972 |